Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect

  title={Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect},
  author={Marina Miguel-{\'A}lvarez and Alejandro Santos-Lozano and Fabi{\'a}n Sanchis-Gomar and Carmen Fiuza-Luces and Helios Pareja-Galeano and Nuria Garatachea and Alejandro Lucia},
  journal={Drugs \& Aging},
IntroductionAlzheimer’s disease (AD) is the cause of more than two-thirds of all dementia cases. Although there is no effective treatment against this disorder, its association with neuroinflammation suggests that non-steroidal anti-inflammatory drugs (NSAIDs) might represent a potential therapeutic option.ObjectiveThe objective of this study was to evaluate the efficacy of NSAIDs in the treatment of AD using a meta-analysis approach.MethodsMEDLINE, Web of Science, Science Direct, and the… 

Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews

Melatonin, statins, antihypertensive drugs, antidiabetic agents, Cerebrolysin, psychostimulants, and some herbal drugs seem to be effective in improving cognitive function of AD patients, but the evidence in this regard is limited.

Recommendations for Anti-inflammatory Treatments in Alzheimer’s Disease: A Comprehensive Review of the Literature

This article provides a comprehensive review of various observational studies and randomized trials encompassing the use of anti-inflammatory agents in the management of AD patients and utilizes the conclusions derived therefrom to give recommendations in this regard.

Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease

A dose–response meta-analysis showed that nonsteroidal anti-inflammatory drugs (NSAIDs) use was not associated with Parkinson disease risk, and the potency and the cumulative NSAIDs use did not play critical roles.

Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?

  • A. Cuello
  • Biology, Psychology
    Trends in pharmacological sciences
  • 2017

Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines

It is suggested that it is crucial for both the pharmacological and complementary medicine industries to conduct and fund studies to significantly advance the field of anti-inflammatory drugs and phytomedicines, as it is not yet clear if the active compounds reach an effective concentration in the brain or if they can slow down AD progression in long-term trials.

New Possibilities in the Therapeutic Approach to Alzheimer’s Disease

Although recent findings from the testing of drugs such as aducanumab are encouraging, they should nevertheless be interpreted cautiously, a long way from having a clinically effective disease-modifying therapy.

Targeting Neuroin fl ammation as a Therapeutic Strategy for Alzheimer ’ s Disease : Mechanisms , Drug Candidates , and New Opportunities

The mechanisms and status of different anti-inflammatory drug candidates for AD that have undergone or are undergoing clinical trials are discussed and new opportunities for targeting neuroinflammation in AD drug development are explored.

Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database

Long term use of oral non-steroidal anti-inflammatory drugs (NSAIDs) is linked with reduced risk of developing Alzheimer’s disease, and data from MedWatch suggest that fluticasone propionate administered intranasally might have a similar preventive effect to ibuprofen.

Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.

DR approaches will create a major paradigm shift in AD research and development, with relatively homogeneous AD subpopulations specifically targeted with existing drugs based on known modes of action.



Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review

Based on analysis of prospective and nonprospective studies, NSAID exposure was associated with decreased risk of Alzheimer’s disease, and an issue that requires further exploration in future trials or observational studies is the temporal relationship betweenNSAID exposure and protection against Alzheimer's disease.

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

Systematic review and meta-analysis of observational studies published between 1966 and October 2002 that examined the role of NSAID use in preventing Alzheimer's disease found NSAIDs offer some protection against the development of Alzheimer's Disease.

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease

Ibuprofen, if used for relatively short periods of time and although well tolerated thanks to gastroprotection, does not seem to be effective in tertiary prevention of mild-moderate AD.

Rofecoxib: No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study

The failure of selective cyclo-oxygenase–2 inhibition to slow the progression of AD may indicate either that the disease process is too advanced to modify in patients with established dementia or that cyclo’s enzyme does not play a significant role in the pathogenesis of the disorder.

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease

Estimation of the overall chance of individuals exposed to arthritis or anti-inflammatory drugs developing AD as compared with the general population and population-based studies with rheumatoid arthritis and NSAID use as risk factors suggest anti- inflammatory drugs may have a protective effect against AD.

No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial

The results of this study are inconclusive with respect to the hypothesis that indomethacin slows the progression of AD.

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease

This pilot study, with small treatment numbers, did not demonstrate a significant effect of NSAID treatment in AD, but the trends observed justify further investigations with a larger number of participants.

Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease

Celecoxib 200 mg bid did not slow the progression of AD in this study, and the occurrence of adverse events was as expected for an elderly population with a complex chronic medical condition.

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study

NSAID use is inversely associated with AD and may be modified by APOE genotype, and Prospective studies and clinical trials of sufficient power to detect effect modification by APoe-ε4 carrier status are needed.

Neuroinflammatory perspectives on the two faces of Alzheimer’s disease

The evidence that inflammation related events could be a critical etiological factor in certain forms of the sporadic AD is reviewed, suggesting that inflammatory mechanisms are most likely involved in the early steps of the pathological cascade.